Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $50 million in capital through a Series-C financing round and the conclusion of a loan facility. Soleus Capital managed the Series C equity financing, which includes the participation of new and current investors, including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures and Saras Capital. Horizon Technology Finance Corporation (Nasdaq: HRZN) provided the credit facility.

By increasing total funding to over $100 million, this funding will enable Parse to advance and further scale its expansion efforts to meet the increasing demand for its technology and continue to serve its academic customers as well as biotech and pharmaceutical customers.

By empoting researchers to perform single-cell sequencing with unprecedented scaling and effortlessness without the need for custom instrumentation, Parse's single-cell portfolio now includes Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect and data analysis solutions.

"The customer resonance to our products was exceptional. Researchers from all over the world are now using our technology to make significant progress," says Alex Rosenberg, Ph.D., CEO and co-founder of Parse. "The overwhelming support of investors will drive our plan to make scalable single-cell projects a routine. We are particularly excited to be able to continue supporting many large-scale programs that are so important for the biopharmaceutical industry."

"The unique technology of Parse enables researchers to carry out groundbreaking research and expand the overall market for genomics," says David Canner, partner of Soleus Capital. "We are proud to partner with Parse and his management team as the company develops into an outstanding player in the field of genomics."

The forward-looking approach and inherent scalability of Parse's technology have led to crucial discoveries in a wide range of research areas that answer researchers' questions more comprehensively than other single-cell products. Within a relatively short period of time, Parse has expanded its basic Evercode technology to enable researchers to open up new areas of application, such as immune profiling and CRISPR pool screening.

"The transformative technology of Parse paves the way for the sequencing of single cells in order to be able to significantly renew and improve research on human health and its forms of treatment," says Gerald A. Michaud, President of Horizon. "We are extremely pleased to be able to support Parse as it develops new genomics solutions and further expands its business activities."

Since its introduction in 2021, Parse's products have received broad approval from leading pharmaceutical companies as well as research universities and institutions. The company's products are now available in a growing number of important international markets, including Australia, Europe, India, Israel, New Zealand, Singapore and South Korea.